3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition


  • Wall Street often ignores stocks with tremendous potential.
  • Esai (ESAIY): The Street is ignoring Eisai’s blockbuster Alzheimer’s treatment. 
  • Entain (GMVHY): Entain could become a takeover target itself. 
  • Stem (STEM): Stem is poised to benefit from increases in the utilization of electricity.
overlooked stocks to buy - 3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition

Source: Shutterstock

If you think about it, many of today’s high-flying stocks were once ignored by the Street. Nvidia (NASDAQ:NVDA) was a struggling video-game chip maker, Amazon (NASDAQ:AMZN) was a fledgling online book seller and Apple (NASDAQ:AAPL) was a formerly successful PC maker, fighting to stay in business. Indeed, the Street tends to shun stocks with great potential that are not yet delivering huge revenue gains or impressive partnerships. Therefore, it’s certainly worthwhile for long-term investors to consider buying stocks that are largely being shunned by the most popular business-news pundits and the largest investors. Here are three such overlooked stocks to buy.

Eisai (ESAIY)

medicine research, pharmaceutical background, LJPC stock
Source: Sisacorn / Shutterstock.com

The Street is still not enthusiastic about Japanese drug maker Eisai (OTCMKTS:ESAIY), co-owner of the first-ever Alzheimer’s treatment, Leqembi, that has shown a significant amount of effectiveness.

According to data reported late last year, 60% of a small group of early-stage Alzheimer’s patients who received the drug meaningfully improved. Among a larger group of patients with varied stages of the disease, cognitive decline was slowed by 27%.

For a variety of logistics-related reasons, the uptake of the drug has been slower than expected. Neurologists have been unenthusiastic about the treatment. Insurers’ reluctance and IV-only delivery likely explains physicians’ reticence.

Thankfully, Eisai has begun seeking FDA approval for a subcutaneous version of Leqembi which should ease the drug’s administration. Additionally, Eisai’s U.S. partner, Biogen (NASDAQ:BIIB), is reportedly working to increase insurance coverage of the treatment.

In spite of the problems, Eisai predicts that the drug will generate almost $2 billion in sales by fiscal year 2027 and $8 billion in revenue in fiscal year 2031.

Entain (GMVHY)

sports betting stocks man celebrating winning bet on match, bookmaker app
Source: Motortion Films / Shutterstock.com

Entain (OTCMKTS:GMVHY), a UK-based online betting giant, delivered strong financial results in 2023. It also may greatly benefit from selling a stake in a joint venture to MGM (NYSE:MGM) and could itself become a takeover target.

Last year, Entain’s revenue climbed 11% to 4.77 billion British pounds, while its operating profit, excluding certain items, jumped 18% to 641.8 million British pounds.

Meanwhile, Entain and MGM’s joint venture, BetMGM, rose 36% last year, and the joint venture generated positive EBITDA in the second half of the year. BetMGM’s revenue and EBITDA are likely to climb tremendously as the platform expands to more states and as the popularity of online betting spreads in the U.S.

There have been rumors that MGM would look to buy Entain’s stake in BetMGM. If that does occur, Entain would likely have several billion dollars of cash that it could return to shareholders or use to acquire a profitable firm.

Further, the London Times recently reported that private equity firms are interested in buying Entain. If that occurs, of course, the company’s shares would soar.

All of Entain’s positive catalysts make it one of the best overlooked stocks to buy.

Stem (STEM)

Conceptual background of artificial intelligence, humans and cyber-business on programming technology element, 3D illustration. Next trillion-dollar companies. top AI stocks billionaires buy
Source: whiteMocca / Shutterstock.com

Stem’s (NYSE:STEM) AI-powered software maximizes the efficiency of electricity use. The electrification of transportation and the rapid proliferation of AI should cause Stem’s software demand to surge going forward.

Stem recently launched PowerBidder Pro to help energy traders and asset owners optimize their asset bids and manage risk. It also enables them, using AI, to predict their energy usage. The product appears to be geared to the owners of energy storage batteries, a sector that’s rapidly growing in America.

Encouragingly, Stem already obtained a major customer and leading independent energy and commodity group, Mercuria, for PowerBidder Pro. Mercuria’s decision to purchase the product so soon after its launch bodes well for its outlook.

Stem expects to generate $50 million of cash this year, making it a prime choice among overlooked stocks to buy.

On the date of publication, Larry Ramer held long positions in STEM, ESAIY and MGM. His wife held a long position in BIIB. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.

Article printed from InvestorPlace Media, https://investorplace.com/2024/04/3-stocks-wall-street-is-ignoring-but-you-shouldnt-april-edition/.

©2024 InvestorPlace Media, LLC